Understanding Oncology Phase 1 Trials And Dose Optimization
Exploring Oncology Phase 1 Trials And Dose Optimization reveals several interesting facts. This lecture is part of the NIH Principles of
Key Takeaways about Oncology Phase 1 Trials And Dose Optimization
- Since the FDA initiated Project Optimus, considerable effort has been stimulated to better select
- Alexandra Drakaki, MD, PhD, University of California, Los Angeles, CA, discusses the
- 0:00 Title Page 2:15 Speaker Introduction 5:15 Webinar Outline 6:05 Project Optimus Overview 8:05 List of approved
- Lillian L. Siu, MD, FRCRC, Princess Margaret
- David J. Kerr, CBE, MD, DSc, discusses considerations for
Detailed Analysis of Oncology Phase 1 Trials And Dose Optimization
This video discusses important concepts to consider for pharmacology and Elizabeth Garrett-Mayer, PhD joined the American Society of Phase I
Ying Lu Stanford University, USA.
Stay tuned for more updates related to Oncology Phase 1 Trials And Dose Optimization.